Introduction
The control of food intake is a complicated process that likely includes inputs and outputs from many sources. Because so many peptides are found in the gastrointestinal tract and because each is released by specific components of food, increased or decreased concentrations of specific peptides could act as signals for satiety and(or) hunger in the control of food intake. More than 20 peptides have been found and are produced by cells scattered throughout the gastrointestinal tract. This wide distribution ensures hormone release regulated by integrated sampling of mixed gastrointestinal contents. The recent improvements in technique for purification of peptides have led to identification of their structure and increased understanding of their release and function. These new techniques have resulted in: 1) development of radioimmunoassays for detection of low concentrations in serum, 2) ability to localize the presence of peptides in specific cells and tissues, 3) identification of stimuli for release and 4) determination of physiological vs pharmacological effects on the gastrointestinal tract. In addition, the new techniques have resulted in re-examination of actions of classical peptides and in the discovery that some peptides are circulating in several molecular forms.
The cells in the gastrointestinal tract thought to contain specific peptides, the location of the cells and the peptides contained in each are listed in table 1. Although the roles for some are relatively well established, e.g., gastrin from the G cells and cholecystokinin from the I cells, the roles for others are only now being investigated; e.g., substance P in the ECI cells and neurotensin in the N cells. This list by no means includes all peptides or cells currently found.
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Gastrointestinal Cells and Peptides
The peptides have been grouped using several characteristics including structure, cell type, mode of action and function. The two main families of peptides are the gastrincholecystokinin (CCK) group and the secretinglucagon group. Gastrin and CCK-4 share the last four C terminal amino acids. Molecular forms of, CCK include CCK-8, CCK-12, CCK-33 and CCK-39 and molecular forms of gastrin are gastrin-12, gastrin-17 and gastrin-34. The other family of peptides is the secretin group, which includes vasoactive intestinal polypeptide, gastric inhibitory peptide and glucagon.
Peptides from the cells of the gastrointestinal tract may have one or more of three modes of action -neurocrine, endocrine or paracrine. Neurocrine transmission acts over very short distances, e.g., synaptic-cleft; endocrine transmission occurs via the blood stream and paracrine transmission occurs by diffusion through the intercellular space to receptors. All three systems use amino acids or derivatives of amino acids, amines or peptides as chemical messengers. Many peptides in the gastrointestinal tract are released during a meal. Radioimmunoassay techniques readily measure concentration changes of peptides of endocrine, but not neurocrine or paracrine modes of action.
The peptides of the gastrointestinal tract may also be grouped by function -either stimulus for release or effects on the gastrointestinal tract. For example, carbohydrate ingestion stimulates rapid release of gastric inhibitory peptide (GIP), neurotensin and enteroglucagon (GLI), while fat ingestion stimulates release of CCK and GIP.
Each gastrointestinal peptide may affect only one of many functions, including I) water and electrolyte secretion, 2) enzyme secretion, 3) growth, 4) endocrine secretion and 5) intestinal absorption. However, these peptides must interact to produce the optimal conditions for digestion of food. For example, food in the stomach causes release of gastrin, which increases gastric motility and acid secretion. Food is then emptied from the stomach into the duodenum, where GIP is released and inhibits the actions of gastrin. Secretin and CCK, which are also released, stimulate pancreatic secretion and may inhibit acid secretion.
An important discovery in the recent past has been localization in the brain of peptides thought to be only in the gastrointestinal tract. Similarly, peptides thought to be only in the brain have been found in the gastrointestinal tract. These include those listed in table 2. It appears that the peptides may be acting as neurotransmitters in the brain, and the gut, e.g., vasoactive intestinal polypeptide and neurotension. Gastrin and CCK have been found to affect gastric secretion and food intake, respectively, when administered both centrally and systemically (DellaFera and Baile, 1979; Tepperman and Evered, 1980) . Pearse and Polak (1978) proposed that these brain-gut peptides may have a common link because of certain characteristics. They were proposed toJbe part of the APUD series (amine precursor uptake and decarboxylation) and to originate in the neuroectoderm. However, more recent evidence suggests that the presence of the same peptides in the gastrointestinal tract and in the brain is a consequence of the capacity of all cells to produce a particular peptide (Dockray, 1979) .
Gastrointestinal Cells and Food Intake
The peptides have been divided into three groups. The first group is peptides that have been tested and found not to affect food intake. The second group of peptides include those that have not been reported to have been tested for effects on food intake and Bayliss and Starling (1902) . It is released from the S cell primarily by acid pH in the duodenum, although changes in serum concentrations of secretin after a meal have been found to be very small (Rayford et al., 1976; Burhol et al., 1979) . Secretin stimulates water and bicarbonate secretion from the exoerine pancreas and liver and potentiates CCK-stimulated enzyme secretion from the pancreas (Hubel, 1972) . In rats, as much as 10 clinical units/kg Of secretin did not affect food intake (Gibbs et al., 1973b) . Gastric inhibitory peptide (GIP) is released from K cells primarily in the duodenum by fat and hexose. Peterson and Brown (1972) reported that GIP inhibited gastric acid secretion and, only in the presence of glucose, stimulated release of insulin from the pancreas. Because of this action, it was suggested the name be changed to glucose-dependent insulin releasing peptide. The GIP release in response to glucose was enhanced in patients with diabetes and obesity (Brown et al., 1975) . Administration of up to 100 /ag/kg GIP did not affect food intake in rats (Lorenz et al., 1979) .
Gastrin has been localized in the G cells primarily in the antrum of the stomach and the central nervous system (CNS); primarily the hypothalamus, infundibulum, pituitary and medulla (Rehfeld, 1978) . Gastrin is released by distension and protein and serum concentrations of G~17 and G-34 were increased after a meal (Taylor et al., 1979) . Gastrin causes release of gastric acid into the stomach and maintains growth of the gastric mucosa (Johnson, 1974) . Injection of gastrin into the lateral hypothalamus also stimulated gastric acid output in rats (Tepperman and Evered, 1980) . While systemic gastrin administration did not affect food intake of rats,, injection of relatively high doses of pentagastrin into the lateral cerebroventricles of sheep decreased food intake (Della-Fera and Baile, 1979) .
Neurotensin has been localized in the N cells of the jejunum and ileum and in the brain, especially the hypothalamus (Carraway and Leeman, 1973; Lundquist et al., 1979) . While the stimulus for release is unknown, neurotensin has been reported to induce hypotension, gut contraction and hyperglycemia (Carraway and Leeman, 1973 ; Brown and Vale, i976) . Injection of 2.6 nmol neurotensin into the ventromedial hypothalamus (VMH) did not affect food intake of satiated rats (Grandison and Guidotti, 1977) .
Somatostatin has been found in D cells throughout the gastrointestinal tract, including the stomach and pancreas (Hokfelt et al., 1975) . It has widespread effects, mostly inhibitory. In the stomach, it inhibits several functions, likely by paracrine action, and in the pancreas, it inhibits the actions of insulin, glucagon and pancreatic polypeptide (Creutzfeldt and Arnold, 1978; Larsson et al., 1979; Lundquist et al., 1979) . Percentage increase in gastrin from perfused stomach remained constant in the presence of somatostatin. But, when activity of somatostatin was blocked by antibody, percentage increase in gastrin was increased, indicating that somatostatin was exercising continuous restraint on gastrin secretion (Saffouri et al., 1979) . Injection of 2.1 nmol of somatostatin, also found in the brain, in the VMH of satiated rats did not affect food intake (Grandison and Guidotti, 1977) .
While these hormones have been tested in at least one experiment for effects on food intake, some of the newer peptides have not, including vasoactive inhibitory polypeptide, substance P, motilin and enteroglucagon. Vasoactive inhibitory polypeptide (VIP) has been found in relatively high concentrations in the D1 cell of the duodenum and colon and in specific areas of the brain, including supraoptic nucleus, suprachiasmic nucleus and lateral preoptic area. It is widely distributed in neurons in the CNS as well as periphery, but its localization in endocrine cells is in question. While the role of VIP in the CNS is unknown, it has been shown to affect vasodilation and smooth muscle contraction in the gastrointestinal tract as well as pancreatic function (Fahrenkrug, 1979) . Serum concentrations of VIP released by fat, increased after a meal (Schaffalitzky de Muckadell et al., 1977) .
Substance P has been located in neuronal and EC1 endocrine cells of the gastrointestinal tract, especially in the duodenum and in subcortical regions of the brain, including the hypothalamus. In the CNS, substance P has characteristics of a neurotransmitter, and in the gastrointestinal tract, it has effects on blood flow and smooth muscle (Mroz and Leeman, 1977; Lundquist et al., 1979; Holzer et al., 1980) .
Motilin has been localized in the brain and in the EC2 cells of the small intestine. Plasma concentrations of motilin, released by fat and acid in the duodenum, were increased within 30 min. It stimulated gastrointestinal motor activity (Lee et al., 1980) .
Glucagon-like immunoreactive D cells were found in both pancreas and gastrointestinal tract. Although the structures of glucagon in the two areas appear to be the same, activities differ. Glucagon of gastrointestinal origin has been termed enteroglucagon. While enteroglucagon, released by ingestion of glucose, increased following a meal, pancreatic glucagon did not (Bloom, 1974) .
Peptides not Tested for Effects on Food Intake. In table 3 is a list of some of the gastrointestinal peptides that have been identified but not tested for a possible role in the control of food intake. Although they have been isolated from the gastrointestinal tract, named and structures characterized, they are too new for much to have been learned regarding their functions.
Peptides Shown to Affect Food Intake. The first, and what currently appears to be the most important peptide that may play a role in the control of food intake, is cholecystokinin (CCK). CCK, localized in the I cells in the duodenum and jejunum, has been shown to be released primarily by the amino acid and fatty acid components of a meal (Meyer, 1974) . The physiological actions of CCK in the gastrointestinal tract include contraction of the gall bladder and stimulation of enzyme and peptide release from the pancreas (Shaw et al., 1973; Regan et al., 1980; Rehfeld et al., 1980) . Other, probably pharmacological effects include contraction of the active stomach and pyloric sphincter and increased motility and transit rate of the small intestine (Debas et al., 1975; Scott and Summers, 1976) . CCK is one of several peptides found in both the gastrointestinal tract and brain. It was found primarily in the cerebral cortex, olfactory bulbs and hypothalamus (Saito et al., 1980) , and concentrations were 10 to 100 times those of other peptides found in the brain (Dockray, 1980) . The highest receptor binding occurred in areas with the highest concentrations of CCK (Saito et al., 1980) .
In studies of the structure and function of CCK, at least six molecular forms have been identified. CCK-3 and CCK-4 are common to the peptide gastrin. CCK-8 was the predominant form and comprised 95% of the CCK in the brain and 40% in the gastrointestinal tract (Rehfeld and Kruse-Larsen, 1978; Dockray, 1980) . Also found were CCK-12, CCK -33, (which was the original molecular form identified), and CCK-39. Investigators have discovered that potencies of the different molecular forms of CCK differ with gastrointestinal effect being measured. CCK-4 was found to be a potent releaser of all four pancreatic hormones, but had little affect on the exocrine pancreas; while CCK-8 and CCK-33 were" more potent stimulators of the exocrine pancreas and had little affect on the endocrine pancreas (Rehfeld et al., 1980) . Using radioimmunoassays with increasing purity of CCK-33 as an antigen, investigators showed that serum concentration increased during a meal (Rehfeld and KruseLarsen, 1978) . However, as CCK-8 had been (Gibbs et al., 1973a) . In subsequent years, various forms of CCK have been shown to decrease food intake in man (Sturdevant and Goetz, 1976) , monkeys (Gibbs et al., 1976) , mice (Koopmans et al., 1972) , cats (Mendel et al., 1980) , sheep (Della-Fera and and rabbits (Houpt et al., 1978) . That a peptide decreases food intake does not necessarily mean that it is acting as a satiety peptide. Thus, Gibbs et al. (1973b) proposed several criteria to test for the role of CCK in satiety:
1) It should be activated as a consequence of feeding. 2) It should significantly decrease meal size.
3) It should have a relatively rapid onset and brief duration of action. 4) Its effects should not be due to illness. 5) It should be effective in physiological doses. Gibbs et al. (1979) included evidence that CCK fulfills each of these criteria. The action of CCK on meal size was relatively brief, especially when lower doses were used. Within 1 to 2 h, food intake of rats, injected with CCK, was not different from that of rats injected with saline. Indeed, Sturdevant and Goetz (1976) have shown the half-life of CCK is 2 to 3 min.
Some investigators have challenged that the effect of CCK is not due to illness. Citing evidence from lithium chloride aversion tests and from effects of CCK on duodenal motility, Deutsch and Hardy (1977) and Deutsch et al. (1978) proposed that injections of CCK caused aversion and produced changes in duodenal motility different from those occurring during normal feeding. However, Antin et al. (1975) have shown that after CCK injection, rats exhibit the sequence of normal satiety behaviors after a meal. The question of whether the doses were physiological remains.
In future experiments CCK should be tested after normal intermeal intervals, making possible use of lower doses of CCK to elicit satiety. These lower doses may produce serum concentrations more like those occurring during normal feeding.
Researchers have investigated the satiety effects of CCK when administered centrally in sheep and systemically in Zucker obese rats. In sheep, research was initiated at the same time CCK was being discovered in the brain. Della-Fera and Baile (1979) have shown that continuous injection of as little as .01 pmol/min CCK into the lateral ventricle of sheep decreases food intake. This concentration was similar to that found in the cerebrospinal fluid (CSF) by Rehfeld and Kruse-Larsen (1978) . Also, concentrations of CCK in CSF increased with feeding and subsequently decreased . One way to determine the role of a peptide is to measure the effect of its absence. To bind the CCK present in the brain, antibody in serum of rabbits was injected continuously. Compared with food intake of sheep injected with nonantibody-containing serum, that of sheep injected with antibody-containing serum increased. Thus, the absence of CCK stimulated feeding (Della-Fera et al., 1981) . have postulated that CCK may be released from specific areas of the brain by signals from the gastrointestinal tract. Acting as a neurotransmitter it may then be carried via the CSF to receptor sites to terminate feeding.
In obesity, the question of whether food intake is increased remains to be clarified. Clearly, however, for obesity to develop, food intake must exceed energy expenditure over long periods of time. The inability to balance energy intake with energy expenditure may be due to increased hunger and(or) decreased satiety. If CCK is a satiety peptide, then the obese may have decreased circulating concentrations of CCK or decreased sensitivity to CCK. McLaughlin and Baile (1980b) have demonstrated that Zucker obese rats have decreased sensitivity to CCK-8 when injected just before meals scheduled 2 h apart (figure 1). The first meal size was decreased by CCK in a dose-dependent manner in both lean and obese rats, but the decrease was less for obese rats for each dose and across doses. Similar results were obtained for the cumulation over four meals. It was demonstrated that this decreased sensitivity occurs as early as 3 wk of age (McLaughlin and Baile, 1980a) . The feeding response to CCK has been measured in another genetically obese rodent, the Bar Harber obese mouse (ob/ob; McLaughlin and Baile, 1981) . In adult mice, 1 /~g/kg CCK-8 decreased food intake to 50% of control in lean mice, but did not significantly affect food intake in obese mice. However, obese and lean mice responded similarly to 2.0 ~tg/kg CCK-8. This decreased sensitivity of Bar Harbor obese mice to CCK is evident by 5 to 6 wk of age (McLaughlin and Baile, 1981) . Others have shown VMHlesioned obese rats to be less sensitive to satiety by CCK (Stern et al., 1976; Krinsky et al., 1979) .
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If CCK was a satiety signal and if the obese were less responsive to this signal, if may be because they have lower concentrations of or decreased sensitivity to normal concentrations of CCK. Straus and Yalow (1979) have shown that the concentrations of CCK in the cerebral cortex of obese mice are only one-third those of lean mice. Others have found that concentrations of CCK do not differ in obese and lean mice (Schneider et al., 1979) .
We are developing a bioassay to determine CCK-like activity of serum by measuring the amylase released from dispersed pancreatic acini. The activity was increased by serum from rats injected with CCK -8 and the amylase released in the medium by serum from obese rats was greater than that by serum from lean rats (McLaughlin and Baile, 1981) . This indicates increased rather than decreased concentration of CCK in serum from obese rats. If, in subsequent experiments these findings are supported, the results imply that receptor number and(or) sensitivity for CCK may be decreased in the obese. In the future, means may be developed to increase receptor sensitivity or provide increased concentrations of CCK to help control food intake in the obese. While the literature data suggest that CCK may be a gastrointestinal peptide involved in the control of food intake, much research remains. For example, what are serum concentrations of CCK during feeding and fasting and where is the receptor for the effect of CCK on satiety?
Bombesin (BBS), found in both the brain and gut, is another putative satiety peptide. Originally isolated from amphibian skin (Anastasi et al., 1971) , BBS has recently been demonstrated by immunohistochemical techniques to be present in the mammalian gastrointestinal tract and in the brain at even higher concentrations (Bloom and Polak, 1978) . The effects of BBS on the gastrointestinal tract include stimulation of release of amylase from the pancreatic acinar cell in vitro and in vivo, stimulation of pancreatic polypeptide release, contraction of the gallbladder, stimulation of gastrin release and increase in frequency of the pace setter potentials in the duodenum and upper jejunum (Basso et al., 1975; Caprilli et al., 1975; Erspamer and Melchiorri, 1975) . Central injections of BBS have been shown to cause prolonged hypoglycemia, hyperglucagonemia and hypoinsulinemia and very low doses cause core hypothemia (Brown et al., 1977; .
With the radioimmunoassay techniques currently available, serum concentrations of BBS have not been measurable under fasting or feeding conditions. Whether BBS concentrations increase during a meal, what the possible stimuli for release are and whether the effects measured are physiological or pharmacological, remain to be determined. BBS has, in spite of this, been shown to decrease food intake in rats fed solid or liquid diets (Gibbs et al., 1979) and to elicit the normal sequence of satiety behaviors (Martin and Gibbs, 1980) . Bombesin, in addition to eliciting satiety when administered systemically, also decreased food intake when administered centrally. Della-Fera and Baile (1980) showed that continuous injection of 2 pmolBBS/min in the lateral ventricle of sheep decreased food intake. Bolus injections of BBS in lateral ventricles of rats also decreased food intake (Grinker et al., 1980) . The feeding responses of obese rats and mice to BBS have been compared and, while the obese were less sensitive to CCK, they were equally sensitive to BBS. In Zucker obese rats, injection of BBS decreased food intake in a dose-dependent manner. The responses were not different from those demonstrated in lean rats after a 5.5 h fast and from 4 to 10 wk of age (McLaughlin and Baile, 1980a) . In Bar Harbor obese mice, BBS decreased food intake less than in lean mice 5 to 6 wk of age, but the same as in adult lean mice (McLaughlin and Baile, 1981) . Evidence has been presented for the possible role of BBS as a satiety component in the control of food intake whether BBS is administered centrally or systemically.
Opiates, long known for producing euphoria and analgesia, have recently been discovered to be endogenous peptides located in both brain and gastrointestinal tract. The name "pro-opiocortin" has been given to a precursor molecule that is the parent of amelanocyte stimulating hormone, adrenocorticotropin, /3-lipotropin and /3-endorphin (Rubinstein et al., 1978) . /3-endorphin was localized primarily in the hypothalamus and intermediate lobe of the pituitary. High concentrations of two smaller, rapidly metabolized opioid peptides, leu-and met-enkephalin, were found in the same areas of the brain as 3-endorphin, but not in the same neurons (Blood et al., 1978) . In addition, the concentrations of these opioids appeared to be independent of each other and independently regulated in hypothalamus and pituitary (Rossier et al., 1977; Bloom and Polak, 1978) . Enkephalins have been found in high concentrations all along the gastrointestinal tract. There is evidence that they may have a role in control of motility (Nijkamp and Van Ree, 1980) , stimulate release of insulin and glucagon, but inhibit release of somatostatin (Ipp et al., 1978) . Because /3-endorphin was localized in both cell bodies and cytoplasm, it may act as both a neurotransmitter and hormone.
The role of opioids in the control of food intake has been investigated. In both sheep and rats, central injections of opioids have increased food intake. As shown in figure 2, (Baile et al., 1982) it is demonstrated that continuous injection of 2.6 nmol/min of enkephalinamide in the lateral ventricle of satiated sheep increased intake. A single injection of 13-endorphin in the lateral ventricle of rats also increased food intake (Kenny et al., 1978) . The effect may have occurred in the ventromedial hypothalamus because injections in this site also increased food intake (Grandison and Guidotti, 1977) .
Support for opiates playing a role in the control of food intake has included the use of naloxone, a specific antagonist. In rats and mice, naloxone administration decreased food intake whether administered acutely or chronically (Kenny et al., 1978; Brands et al., 1979) and also suppressed water intake (Frenk and Rogers, 1979) . In figure 2 is the feeding elicited by enkephalinamide. An opiate antagonist, 3,4 (hydroxyl -phenyl) -3,3 -dimethyl-piperidine propiophenone maleate, decreased food intake when injected alone and also blocked food intake stimulated by an enkephalin-like compound (Baile et al., 1982) .
If opiates are playing a role in the hungersatiety circuit and increased concentrations stimulate feeding, then obese animals may be postulated to have increased concentrations of opiate-like compounds. Rossier et al. (1979) have shown thatat 4 mo of age, ob/ob mice have three times the/3-endorphin in the pituitary as lean mice. However, because the concentrations were not significantly elevated until then, the authors concluded that the elevated pituitary /3-endorphin concentrations were a consequence rather than a cause of obesity. In the same experiment in obese mice, posterior pituitary leu-enkephalin concentrations were at least three times greater than in lean mice by 1 mo of age, which might have been related to causes rather than consequences of obesity. More systematic measurements of/3-endorphin and enkephalin concentration in brain and pituitary are necessary to demonstrate if they are related to obesity. In addition to measuring elevated pituitary /3-endorphin concentrations in both ob/0b mice and Zucker fatty rats, Margules et al. (1978) have shown that percentage of control food intake was decreased by naloxone more in obese than lean mice. In Zucker obese rats, these findings were repeated when injections were made during the initiation of the dark portion of the diurnal cycle. However, when the injections were made after a 6-h fast in the light, lean rats responded more than obese. In rats made obese by lesions in the ventromedial hypothalamus, naloxone decreased food intake more than in lean rats, but not when thi~y were fed a more palatable diet (King et al., 1979) . Thus, opiates may play a role in the control of food intake. Because administration of opiates stimulates food intake, concentrations may gradually increase during the interval following a meal and stimulate initiation of the subsequent meal. Studies with naloxone have supported this possibility because injections of naloxone decreased food intake. In addition, naloxone has been shown to antagonize the effects of other types of chemicals known to stimulate food intake . Another peptide that may have a role in the control of food intake is pancreatic polypeptide. Bovine pancreatic polypeptide (bPP) was discovered by Chance and associates (Lin and Chance, 1980) in the process of investigating impurities in insulin preparations. In subsequent research, it has been shown that 93% of the PP-containing D2 cells were in the duodenal portion of the pancreas in close association with glucagon cells (Adrian et al., 1978; Lundquist et al., 1979) . While PP has not been found in the gastrointestinal tract per se, it may have effects on the control of food intake. Amino acids and fat, but not glucose, stimulated release of PP, and serum concentrations increased two-to threefold within 15 min (Adrian et al., 1978; Schwartz et al., 1978) . This rise in serum concentration was followed by a slight fall in 30 to 60 min. Levels remained elevated for more than 5 h (Schwartz et al., 1978) . As demonstrated earlier, CCK-4, which was released during feeding, was found to be a potent stimulus for PP release from the pancreas (Rehfeld et al., 1980) , as were GIP, VIP and caerulein (Adrian et al., 1978) . Although the effects of physiological concentrations of PP have not been clearly demonstrated, relatively low concentrations have 1) suppressed pancreatic secretion induced by Asterisks (* and **) denote that food intake after pancreatic polypeptide injection was different from that after saline injection (paired t-test; P<.05 and P<.01, respectively). A = percentage of control food intake for obese different from lean, (paired -t; P<.O5). exogenous or endogenous CCK plus secretin, 2) enhanced gastric emptying and intestinal transit and 3) first stimulated and then inhibited small intestine motility (Lin and Chance, 1980) . Serum concentrations of PP, in addition to increasing during a meal, were higher in humans that were older (Floyd et al., 1978) or had diabetes (Adrian et al., 1978) . Although the role for PP in satiety remains unclear, obese humans had decreased circulating concentrations of PP and decreased release in response to a protein-rich meal (Lassman et al., 1980; Marco et al., 1980) . In obese rodents, serum concentrations of PP have not been established, while pancreatic content of PP has been reported to be both increased (Gingerich et al., 1978) and decreased (MalaiseLagae et al., 1977; McLaughlin and Baile, 1981) .
If the decreased serum concentrations of PP are related to obesity, then one might predict that exogenous administration of PP would attenuate obesity. Malaisse-Lagae et al. (1977) have shown that chronic administration of PP in Bar Harbor obese mice decreased body weight compared with salineinjected control obese mice. Unfortunately, effects of similar injections in lean mice have not been reported; thus, the effects measured in this experiment may not be specific for obese animals. Similar chronic injections in New Zealand obese mice decreased weight gain in obese mice, but not lean mice (Gates and Lazarus, 1977) . In addition, after injection of PP, plasma insulin and glucose were decreased in obese mice injected with PP but not lean mice. Thus, supplying of PP may reduce body weight, hyperglycemia and hyperinsulinemia of obese mice. We have demonstrated that the effect may be directly on food intake which may be followed by the changes described (McLaughlin and Baile, 1981) . After a 3 -h fast the lower concentration of 8 #g/kg decreased food intake of lean but not obese mice, while higher concentrations decreased food intake of both obese and lean mice (figure 3). After a 6-h fast neither obese nor lean mice responded to 16 #g/kg and there was a trend for the obese to respond more than the lean to 32 /ag/kg. This last concentration is closer to that used in the studies previously described and it could be that the obese are more sensitive to higher but not lower concentrations of PP. Results of this experiment demonstrate that food intake of lean mice as well as obese mice can be decreased by PP. In similar experiments with rats, however, up to 128/ag/kg PP had no effect on food intake.
Thus, PP, a relatively new peptide, may play a role in the control of food intake; much remains to be learned regarding its role in satiety as well as its physiological role in the gastrointestinal tract.
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